Comparison on the efficacy of the two drugs combined with trabeculectomy for the treatment of neovascular glaucoma

Abstract

Objective To compare the clinical efficacy of Conbercept and Ranibizumab combined with trabeculectomy for the treatment of neovascular glaucoma (NVG). Methods Sixty-eight eyes of 68 patients with NVG from June 2014 to May 2015 were randomly divided into Conbercept group and Ranibizumab group. Each group contained 34 eyes of 34 cases. The two groups respectively received intravitreal injection of Conbercept or Ranibizumab. All the patients underwent trabeculectomy after iris new vessels disappeared and the intraocular pressure was stable. The panretinal photocoagulation was performed as early as possible. After operation, the patients were followed up for 7-12 months. Results There was no significant difference in successful rate of intraocular pressure control, recurrence rate of iris or chamber angle neovascularization, visual acuity or the incidence of complication between the two groups at the end of follow-up (P>0.05). The extinction time of iris and chamber angle neovascularization in Conbercept group (3.22±0.74)d was shorter than that in ranibizumab group (3.84±0.85)d (P 0.05). Conclusion Intravitreal injection of Conbercept or Ranibizumab, combined with trabeculectomy in treating NVG all can promote extinction of neovascularization of iris and chamber angle , control intraocular pressure, and improve visual acuity. But intravitreal injection of Conbercept has the advantage in shortening the extinction time of neovascularization. Key words: Glaucoma, neovascular; Intravitreal injection, Conbercept, Ranibizumab; Trabeculectomy